In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.

Short-term safety profile of Sars-Cov2 vaccination on glucose control. Continuous glucose monitoring data in people with autoimmune diabetes / D'Onofrio, L.; Coraggio, L.; Zurru, A.; Carlone, A.; Mignogna, C.; Moretti, C.; Maddaloni, E.; Buzzetti, R.. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 179(2021), pp. 1-3. [10.1016/j.diabres.2021.109022]

Short-term safety profile of Sars-Cov2 vaccination on glucose control. Continuous glucose monitoring data in people with autoimmune diabetes

D'Onofrio L.
;
Coraggio L.;Zurru A.;Carlone A.;Mignogna C.;Moretti C.;Maddaloni E.;Buzzetti R.
2021

Abstract

In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.
File allegati a questo prodotto
File Dimensione Formato  
DOnofrio_Short-term-safetyprofileSars-Cov2vaccination_ 2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 618.03 kB
Formato Adobe PDF
618.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1573592
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact